FARMAKOLOGI ALPRAZOLAM DALAM MENGATASI GANGGUAN PANIK
Abstract
Abstrak. Gangguan panik merupakan suatu pengalaman serangan panik yang tidak diharapkan yang diikuti oleh ketakutan yang menetap tentang kemungkinan berulangnya serangan. Gangguan panik cenderung diturunkan dengan onset biasanya di bawah usia 25 tahun, mempengaruhi 3-5% populasi, dan rasio wanita dibandingkan laki-laki sebesar 2:1. Golongan benzodiazepine digunakan secara luas untuk penanganan keadaan cemas akut dan untuk kontrol cepat gangguan panik. Alprazolam, suatu triazolobenzodiazepine, bekerja pada kompleks reseptor GABAA_ Benzodiazepine. Sistem kimiawi dan reseptor GABA menghasilkan inhibisi atau efek menenangkan. Alprazolam pada system saraf pusat. Alprazolam dalam jangka waktu pendek (sampai 8 minggu) sangat efektif digunakan pada penanganan gangguan panik dan agoraphobia dan tampak lebih selektif pada kondisi tersebut dibandingkan obat-obat golongan benzodiazepine lainnya.
Abstract. Panic disorder refers to the experience of unexpected panic attacks accompanied by persistent apprehension about their recurrence. Panic disorder tends to be familial, with onset usually under age 25, it affects 3-5% of the population, and the female-to-male ratio is 2:1. Benzodiazepines are widely used to manage acute anxiety state, and for rapid control of panic disorder. Alprazolam, a triazolobenzodiazepine, produce a variety of therapeutic and adverse effects by binding to the benzodiazepine site on the GABAA receptor and modulating the function of the GABA receptor, the most prolific inhibitory receptor within the brain. The GABA chemical and receptor system produces inhibitory or calming effects of alprazolam on the central nervous system. Alprazolam, in the short term treatment (until 8 weeks), highly effective to treat panic disorder and agoraphobia, and seem more selective in that condition than other benzodiazepines.
Keywords
References
Milrod, Leon, Busch, et al. A Randomized Controlled Clinical Trial of Psychoanalytic Psychotherapy for Panic Disorder. Am J Psychiatry. 2007. 164 : 265-272.
Martin, Andres, Volkmar Fred R. Lewis’s Child and Adolescent Psychiatry : A Comphrehensive Textbook. 4th Edition Lippincott Williams & Wilkins. 2007.
McPhee SJ. Papadakis MA. Tierney Jr LM. editors. Current Medical Diagnosis & Treatment. McGraw-Hill. 2008.
Katzung BG. editor. Basic and Clinical Pharmacology. Edisi 10. McGraw-Hill. 2006.
Ian MA. Ian CR. editors. Fundamentals of Clinical Psychopharmacology Second edition. Taylor & Francis e-Library. 2005.
Maslim, R. Panduan Praktis Penggunaan Klinis Obat Psikotropik. Bag. IKJ FK-Unika Atma Jaya : Jakarta. 2002.
Skelton KH, Nemeroff CB, Owens MJ (October 20, 2004). “Spontaneous withdrawal from the triazolobenzodiazepine alprazolam increase cortical corticotrophin- releasing factor mRNA expression”. J Neurosci 24 (42) : 9303-12.
Chouinard G 2004. ”Issues in the clinical use of benzodiazepines : potency, withdrawal, and rebound”. J Clin Psychiatry 65 (Suppl 5) : 7-12.
Mandrioli, R, Mercolini, L. Raggi, MA. Oct 2008. “Benzodiazepine metabolism: an analytical perspective.” Curr Drug Metab 9 (8) : 827-44.
Bandelow B. Zohar J. Hollander E. Kasper S. Moller HJ. Oct 2002. “World Federation of Societies of Biological Psychiatry (WFSBP) : guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders”. World J Biol Psychiatry 3 (4) : 171-99.